Earnings calendar/AMLX
Amylyx Pharmaceuticals, Inc. (AMLX)
Pre-earnings consensus targets and post-earnings beat/miss — standardized metrics from the earnings calendar. No narrative, no price targets.
Pre-earnings
Consensus targets for the next print, plus how the business has been running.
Next report
Nov 5, 2026
Consensus estimate row
EPS target
$-0.38
Street estimate
Revenue target
$59,429
Street estimate
Trailing EPS (avg 4Q)
$-0.36
Beat rate last 4: 50%
Latest EPS YoY
+15.2%
vs 2025-08-07
Latest revenue YoY
—
How results look so far
Trailing revenue (avg 4Q)
—
Printed quarters
EPS beat rate (4Q)
50%
Share of quarters that beat EPS est.
Post-earnings
Did the company hit the target? Actual vs estimate and surprise.
Last print
Aug 6, 2026
EPS miss
EPS actual / est
$-0.39 / $-0.36
-8.1%
Revenue actual / est
— / —
—
Result
Below target
Based on EPS vs consensus
Earnings history
Estimate vs actual and surprise % by print date
| Date | EPS est | EPS act | EPS surprise | Rev est | Rev act | Rev surprise |
|---|---|---|---|---|---|---|
| 11/5/2026upcoming | $-0.38 | Pending | — | $59,429 | Pending | — |
| 8/6/2026 | $-0.36 | $-0.39 | -8.1% | — | Pending | — |
| 5/7/2026 | $-0.34 | $-0.37 | -8.8% | — | Pending | — |
| 3/3/2026 | $-0.31 | $-0.30 | +3.2% | $-52,000 | Pending | — |
| 11/6/2025 | $-0.43 | $-0.37 | +14.0% | $52,000 | Pending | — |
| 8/7/2025 | $-0.44 | $-0.46 | -4.5% | — | Pending | — |
| 5/8/2025 | $-0.45 | $-0.42 | +6.7% | — | Pending | — |
| 3/4/2025 | $-0.49 | $-0.55 | -12.2% | — | $665,000 | — |
| 11/7/2024 | $-0.60 | $-1.07 | -78.3% | $31.6M | $416,000 | -98.7% |
| 8/8/2024 | $-0.38 | $-0.73 | -92.1% | $10.7M | $1.0M | -90.4% |
| 5/10/2024 | $-0.00 | $-0.46 | -11400.0% | $98.3M | $88.6M | -9.9% |
| 5/9/2024 | $0.24 | $-0.46 | -291.7% | $98.3M | $88.6M | -9.9% |
| 2/22/2024 | $0.23 | $0.07 | -69.6% | $107.0M | $108.4M | +1.4% |
| 11/9/2023 | $0.44 | $0.30 | -31.8% | $107.8M | $102.7M | -4.8% |
| 8/10/2023 | $0.10 | $0.31 | +210.0% | $92.1M | $98.2M | +6.6% |
| 5/11/2023 | $-0.24 | $0.02 | +108.3% | $87.6M | $71.4M | -18.5% |
| 3/13/2023 | $-0.77 | $-0.65 | +15.6% | $59.0M | $21.9M | -62.9% |
| 11/10/2022 | $-0.97 | $-0.92 | +5.2% | $83,333 | $345,000 | +314.0% |
| 8/11/2022 | $-0.92 | $-0.93 | -1.1% | $125,000 | Pending | — |
| 5/12/2022 | $-0.75 | $-0.93 | -24.0% | $83,333 | Pending | — |
| 3/30/2022 | $-0.64 | $-4.15 | -548.4% | — | Pending | — |
| 1/10/2022 | — | $-0.42 | — | — | $285,000 | — |
| 6/30/2021 | — | $-0.48 | — | — | Pending | — |
| 3/31/2021 | — | $-0.32 | — | — | Pending | — |
| 12/31/2020 | — | $-0.19 | — | — | $350,000 | — |
Need AMLX data in your own agent or pipeline?
The earnings data on this page — report dates, consensus EPS/revenue estimates, actuals and surprise history — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.